(Q46078255)

19 December 2017

title

Valsartan regulates the interaction of angiotensin II type 1 receptor and endothelial nitric oxide synthase via Src/PI3K/Akt signalling (English)

1 reference

19 December 2017

0 references

3

1 reference

19 December 2017

Song-Kun Shyue

Song-Kun Shyue

9

0 references

Tzong-Shyuan Lee

Tzong-Shyuan Lee

10

0 references

Hsin-Han Hou

7

Hsin-Han Hou

1 reference

19 December 2017

Ching-Chian Pan

8

Ching-Chian Pan

1 reference

19 December 2017

author name string

Kuo-Hui Su

1

1 reference

19 December 2017

Jin-Yi Tsai

2

1 reference

19 December 2017

An-Na Chiang

4

1 reference

19 December 2017

Sheng-Huang Hsiao

5

1 reference

19 December 2017

Yuh-Lin Wu

6

1 reference

19 December 2017

publication date

23 March 2009

1 reference

19 December 2017

published in

Cardiovascular Research

1 reference

19 December 2017

volume

82

1 reference

19 December 2017

issue

3

1 reference

19 December 2017

page(s)

468-475

1 reference

19 December 2017

Evidence based management of hypertension. Cardiovascular risk factors and their effects on the decision to treat hypertension: evidence based review

cites work

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP091

Impact of high-normal blood pressure on the risk of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP091

Valsartan. A review of its pharmacology and therapeutic use in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP091

Valsartan/hydrochlorothiazide: a review of its pharmacology, therapeutic efficacy and place in the management of hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP091

Fixed combination therapy of hypertension: focus on valsartan/hydrochlorothiazide combination (Diovan/HCT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP091

Valsartan, a new angiotensin II antagonist: antihypertensive effects over 24 hours

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP091

Cellular and mucosal immune reactions to mental and cold stress: associations with gender and cardiovascular reactivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP091

Angiotensin II AT1 receptor antagonists inhibit platelet adhesion and aggregation by nitric oxide release

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP091

Transcriptional repression of ATP-binding cassette transporter A1 gene in macrophages: a novel atherosclerotic effect of angiotensin II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP091

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP091

Rho GTPases, statins, and nitric oxide

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP091

Cyclic GMP-dependent protein kinases and the cardiovascular system: insights from genetically modified mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP091

Dissecting the interaction between nitric oxide synthase (NOS) and caveolin. Functional significance of the nos caveolin binding domain in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP091

Dynamic activation of endothelial nitric oxide synthase by Hsp90.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP091

Effect of AT1 receptor blockade on endothelial function in essential hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP091

Inhibitory interactions of the bradykinin B2 receptor with endothelial nitric-oxide synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP091

Role of valsartan and other angiotensin receptor blocking agents in the management of cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP091

Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP091

Shear stress stimulates phosphorylation of endothelial nitric-oxide synthase at Ser1179 by Akt-independent mechanisms: role of protein kinase A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP091

Src-mediated phosphorylation of Hsp90 in response to vascular endothelial growth factor (VEGF) is required for VEGF receptor-2 signaling to endothelial NO synthase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP091

Selective inhibition of vascular endothelial growth factor receptor-2 (VEGFR-2) identifies a central role for VEGFR-2 in human aortic endothelial cell responses to VEGF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP091

Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP091

Losartan inhibits thromboxane A2-induced platelet aggregation and vascular constriction in spontaneously hypertensive rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP091

Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP091

Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP091

Blockade of AT1 receptor reduces apoptosis, inflammation, and oxidative stress in normotensive rats with intracerebral hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP091

Effect of ACE inhibitors and angiotensin II type 1 receptor antagonists on endothelial NO synthase knockout mice with heart failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP091

Valsartan therapy in heart failure after myocardial infarction: the role of endothelial dependent vasorelaxation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP091

Losartan metabolite EXP3179 activates Akt and endothelial nitric oxide synthase via vascular endothelial growth factor receptor-2 in endothelial cells: angiotensin II type 1 receptor-independent effects of EXP3179.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP091

Protein-protein interactions controlling nitric oxide synthases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP091

Hsp90 and caveolin are key targets for the proangiogenic nitric oxide-mediated effects of statins.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP091

Endothelial nitric oxide synthase interactions with G-protein-coupled receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FCVR%2FCVP091

21 January 2018

Identifiers

DOI

10.1093/CVR/CVP091

1 reference

19 December 2017

1 reference

19 December 2017